A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
A phase 1/2 trial of TQB2102 in biliary tract cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT06431490 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 102 participants planned, started 2024-07-22 and due to reach its primary completion in 2027-05. Interventions recorded: TQB2102 for injection.
Similar pages
not linked directly; found by shared links- TrialThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialClinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TreatmentTQB3454
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.